Stock Price Forecast

March 28, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Cullinan Oncology Inc chart...

About the Company

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

CEO

Nadim Ahmed

Exchange

NASDAQ

Website

cullinanoncology.com

$24M

Total Revenue

73

Employees

$742M

Market Capitalization

-4.47

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CGEM News

Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

13d ago, source:

Increased to $34.8 million in Q4 2023 from $33.8 million in Q3 2023, primarily due to increased clinical costs. G&A Expenses: Decreased to $10.6 million in Q4 2023 from $11.0 million in Q3 2023, ...

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

13d ago, source:

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Cullinan Oncology (NASDAQ:CGEM) shareholders is whether they ...

CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023

on MSN ago, source:

Cullinan Oncology (NASDAQ:CGEM) just reported results for the fourth quarter of 2023. Cullinan Oncology reported earnings per share of -54 cents. This was above the analyst estimate for EPS of -96 ...

Cullinan Oncology: Q4 Earnings Insights

14d ago, source:

Cullinan Oncology CGEM reported its Q4 earnings results on Thursday, March 14, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Cullinan Oncology beat estimated earnings by ...

Harbour BioMed Reports Full Year 2023 Financial Results

18h ago, source:

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the ...

Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts

18d ago, source: The Globe and Mail

Aldeyra Therapeutics Inc (ALDX), ALX Oncology Holdings Inc (ALXO ... (CRBU), Comtech Telecommunications Cor (CMTL), Consumer Portfolio Services In (CPSS), Cullinan Oncology Inc (CGEM), Eve Holding Inc ...

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

14d ago, source: TMCnet

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluat ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...